Literature DB >> 2183099

A new animal model of endogenous depression: a summary of present findings.

G Vogel1, D Neill, M Hagler, D Kors.   

Abstract

In 1982 our laboratory proposed a new animal model of endogenous depression. The proposal was that in rats, neonatally administered clomipramine (CLI) will produce adult animals that model endogenous depression. We summarize here several tests of the validity of the model. Results were that after neonatal CLI, adult male rats showed behavioral abnormalities of the human disorder: decreased sexual, aggressive, and intracranial self-stimulation activities, as well as motor hyperactivity in a stressful situation. Preliminary evidence suggested that behavioral abnormalities in rats (sexual, aggressive, and motor) briefly treated with antidepressant treatments (imipramine, REM sleep deprivation) begin to normalize. Lastly, after neonatal CLI, the adult rats showed REM sleep abnormalities of endogenous depression, viz, low REM latency, frequent sleep onset REM periods, and abnormal temporal course of REM rebound after REM sleep deprivation. These results supported the hypothesis that in rats neonatal CLI produced adult animals that modelled endogenous depression.

Entities:  

Mesh:

Year:  1990        PMID: 2183099     DOI: 10.1016/s0149-7634(05)80164-2

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  30 in total

1.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 2.  Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research.

Authors:  Matthew E Glover; Sarah M Clinton
Journal:  Int J Dev Neurosci       Date:  2016-05-07       Impact factor: 2.457

3.  Sleep-related epilepsy in a Long-Evans hooded rat model of depression.

Authors:  Angela L McDowell; Kingman P Strohl; Pingfu Feng
Journal:  Sleep Breath       Date:  2011-12-29       Impact factor: 2.816

4.  Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression.

Authors:  M Vijayakumar; B L Meti
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

5.  Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial infarction in rats.

Authors:  Thierno Madjou Bah; François Laplante; Boubacar Pasto Wann; Ron Sullivan; Guy Rousseau; Roger Godbout
Journal:  Sleep       Date:  2010-12       Impact factor: 5.849

6.  Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats.

Authors:  J Prathiba; K B Kumar; K S Karanth
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Transient postnatal fluoxetine leads to decreased brain arachidonic acid metabolism and cytochrome P450 4A in adult mice.

Authors:  Epolia Ramadan; Helene Blanchard; Yewon Cheon; Meredith A Fox; Lisa Chang; Mei Chen; Kaizong Ma; Stanley I Rapoport; Mireille Basselin
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-01-30       Impact factor: 4.006

8.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

9.  Length of time between onset of childhood sexual abuse and emergence of depression in a young adult sample: a retrospective clinical report.

Authors:  Martin H Teicher; Jacqueline A Samson; Ann Polcari; Susan L Andersen
Journal:  J Clin Psychiatry       Date:  2009-04-07       Impact factor: 4.384

Review 10.  Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.

Authors:  Deepika Suri; Cátia M Teixeira; Martha K Caffrey Cagliostro; Darshini Mahadevia; Mark S Ansorge
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.